Has Panitumumab been approved in China?

Panitumumab is a targeted cancer drug called a monoclonal antibody. It is also known by its trade name Vectibix, and can be used to treat metastatic colorectal cancer ( mCRC) that has spread to other parts of the body ( advanced ). Panitumumab is sometimes used in combination with other chemotherapy treatments, such as FOLFOX and FOLFIRI. Panitumumab is only effective against colon cancer with normal Ras genes. Before treatment with panitumumab, patients will be tested to see if their bowel cancer contains the normal version of this gene.

Panitumumab works by blocking the signals that tell cancer cells to divide and grow. It attaches to a special protein found on the surface of some cancer cells called epidermal growth factor receptor (EGFR). This medication is available as an intravenous infusion and the recommended dose is once every two weeks (14 days), with the first treatment taking approximately 60-90 minutes. If the patient does not experience any discomfort after use, subsequent treatment will take approximately 30-60 minutes. Panitumumab is usually continued as long as it helps the patient and the side effects are not severe.

It is understood that the original version of panitumumab has not been approved for marketing in China, and therefore it has not been included in the scope of medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around 9,000 yuan (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.